Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study (vol 56, pg 770, 2020)

被引：0
作者：
Zamarin, Dmitriy
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2702 / 2702
页数：1
相关论文
共 50 条
  • [21] Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
    Lheureux, Stephanie
    Matei, Daniela E.
    Konstantinopoulos, Panagiotis A.
    Wang, Ben X.
    Gadalla, Ramy
    Block, Matthew S.
    Jewell, Andrea
    Gaillard, Stephanie L.
    McHale, Michael
    McCourt, Carolyn
    Temkin, Sarah
    Girda, Eugenia
    Backes, Floor J.
    Werner, Theresa L.
    Duska, Linda
    Kehoe, Siobhan
    Colombo, Ilaria
    Wang, Lisa
    Li, Xuan
    Wildman, Rachel
    Soleimani, Shirin
    Lien, Scott
    Wright, John
    Pugh, Trevor
    Ohashi, Pamela S.
    Brooks, David G.
    Fleming, Gini F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (03)
  • [22] PHASE II evaluation of dalantercept for persistent or recurrent epithelial ovarian and related cancers: An NRG oncology study.
    Burger, Robert Allen
    Deng, Wei
    Makker, Vicky
    Lankes, Heather A.
    Aghajanian, Carol
    Gray, Heidi J.
    Wade, James Lloyd
    Waggoner, Steven E.
    Levine, Douglas A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
    Bender, David
    Sill, Michael W.
    Lankes, Heather A.
    Reyes, Henry D.
    Darus, Christopher J.
    Delmore, James E.
    Rotmensch, Jacob
    Gray, Heidi J.
    Mannel, Robert S.
    Schilder, Jeanne M.
    Hunter, Mark I.
    McCourt, Carolyn K.
    Samuelson, Megan I.
    Leslie, Kimberly K.
    GYNECOLOGIC ONCOLOGY, 2015, 138 (03) : 507 - 512
  • [24] A randomized phase II/ III trial of nivolumab versus nivolumab plus docetaxel for previously treated advanced or recurrent non-small cell lung cancer: TORG1630.
    Kawashima, Yosuke
    Taniguchi, Yuri
    Shimokawa, Tsuneo
    Takiguchi, Yuichi
    Misumi, Toshihiro
    Nakamura, Atsushi
    Furuya, Naoki
    Tanaka, Kentaro
    Harada, Toshiyuki
    Tanaka, Hisashi
    Miura, Satoru
    Sata, Masafumi
    Kato, Terufumi
    Tokito, Takaaki
    Naoki, Katsuhiko
    Bessho, Akihiro
    Goto, Yasuhiro
    Nakamichi, Shinji
    Okamoto, Hiroaki
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (vol 19, pg 1480, 2018)
    Hodi, F. S.
    Chiarion-Sileni, V
    Gonzalez, R.
    LANCET ONCOLOGY, 2018, 19 (11) : E581 - E581
  • [26] Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial (vol 17, pg 883, 2016)
    Antonia, S. J.
    Lopez-Martin, J. A.
    Bendell, J.
    LANCET ONCOLOGY, 2019, 20 (02) : E70 - E70
  • [27] Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial (vol 17, pg 888, 2016)
    Antonia, S. J.
    Lopez-Martin, J. A.
    Bendell, J.
    LANCET ONCOLOGY, 2016, 17 (07) : E270 - E270
  • [28] Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (vol 19, pg 1480, 2018)
    Hodi, F. S.
    Chiarion-Sileni, V
    Gonzalez, R.
    LANCET ONCOLOGY, 2018, 19 (12) : E668 - E668
  • [29] Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
    Monk, Bradley J.
    Sill, Michael W.
    Walker, Joan L.
    Darus, Christopher J.
    Sutton, Gregory
    Tewari, Krishnansu S.
    Martin, Lainie P.
    Schilder, Jeanne M.
    Coleman, Robert L.
    Balkissoon, Jai
    Aghajanian, Carol
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (19) : 2279 - +
  • [30] Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study
    Tewari, Krishnansu S.
    Sill, Michael W.
    Coleman, Robert L.
    Aghajanian, Carol
    Mannel, Robert
    DiSilvestro, Paul A.
    Powell, Matthew
    Randall, Leslie M.
    Farley, John
    Rubin, Stephen C.
    Monk, Bradley J.
    GYNECOLOGIC ONCOLOGY, 2020, 159 (01) : 79 - 87
12345